Last Updated:
January 02, 2011
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
Estimation of
Virological Residual Activity on a Regimen of Abacavir/Zidovudine/Lamivudine
David Dunn, D Pilla, M
Ranopa
(17th CROI)
PDF
Poster
Abstract
-
Simplification from Trizivir/Kaletra to Trizivir provides a durable treatment
regimen for antiretroviral|
therapy (ART) naïve patients (COL40193)
J. Gathe, Jr., D. Martin, K. Rawlings, et al
Abstract -
Trizivir as part of salvage therapy in a French cohort of heavily pre-treated
HIV-infected patients
failing antiretroviral therapy
P. Pugliese, E. Billaud, L. Cuzin, et al
Abstract -
Trizivir + TDF is a simple and potent therapy regimen in pretreated patients
S. Dupke, T. Berg, B. Hintsche, et al
Abstract
Safety of co-formulated abacavir/lamivudine/zidovudine for treatment of
AIDS-KS in an African setting
M. Borok, I. Gudza, B. Ndemera, et al
Abstract
Safe and effective switch to a triple nucleosidic reverse transcriptase
inhibitors regimen in a
successfully pre-treated French HIV-infected population.
Cuzin L.,
Foucher Y. Agher R. Barone M.
Abstract
Frequency of Abacavir (ABC) Hypersensitivity Reactions (HSR), Rechallenge
Reactions, and
HSR-Attributable Outcomes are similar with the use of Ziagen or Trizivir:
Final Results from the
Trizivir Epidemiology Study
Bartlett J.A., Mole L.A., Fusco J.S., et al
Abstract
Evaluation of lipodystrophy syndrome in HIV-infected patients after
simplification from first-line
antiretroviral treatment with Trizivir™ and
Combivir™ plus nevirapine. SimplifiHAART substudy.
Bonjoch A., Martinez-Lopez E, et al;
Abstract
Quadruple nucleoside/tide regimen of Trizivir (TZV) + Tenofovir (TDF) is
effective following early
virologic failure on an initial regimen containing a thymidine analog +
lamivudine in combination
with
a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor
(NNRTI)
(ESS30005, ZIP)
Rodriguez A., Hill-Zabala C., Sloan , et al
Abstract
-
Analysis of the effect of baseline resistance and clade on 48-week
efficacy of once-daily (OAD)
or twice-daily (BID) abacavir (ABC) in combination with OAD lamivudine
(3TC) and efavirenz (
EFV): a sub-analysis of ZODIAC
G Moyle, D Gordon, J Hernandez, et al
Abstract
-
Lack of efficacy of zidovudine, lamivudine and abacavir as initial therapy
for antiretroviral-naive
patients with AIDS
P Rivas, M Górgolas, A Goyenechea
Abstract-
Long term effects of first-line triple-nucleoside antiretroviral therapy
in a cohort of 205 patients
W Rozenbaum, V Schneider, E Da Silva Marechal, et al
Abstract-
Abacavir, lamivudine and zidovudine (ABC/3TC/ZDV) in antiretroviral-naïve
HIV-infected patients:
multicenter observational cohort from Spain
J
Berenguer, MJ Pérez-Elías, J Bellón, et al
Abstract
-
Long-term efficacy after switch from protease inhibitor (PI)-containing
HAART to abacavir, lamivudine,
and zidovudine
M Opravil, D Baumann, JP Chave, et al
Abstract
-
Efficacy of Trizivir (TZV) and Tenofovir (TDF) as HAART for HIV infected
patients with current or
underlying Reverse Transcriptase (RT) resistance
P Ruane, A Luber, C Gaultier, et
al
Abstract
-
Quadruple nucleoside reverse transcriptase inhibitor (NRTI) therapy with
trizivir® (TZV) and viread®
(TDF) in HAART-naive and -experienced HIV/AIDS patients
P Greiger-Zanlungo, D Rubin, G Blick, T Garton
Abstract
-
An open-label, randomised comparative study of a quadruple NRTI regimen (Trizivir+tenofovir)
versus a
standard of care 2 class triple therapy regimen (Combivir+efavirenz) as
initial therapy for HIV-1 infection
G Moyle, M Nelson, C Higgs, et al
Abstract
-
Efficacy and tolerance of TRIZIVIR in a cohort of advanced naïve patients
as first line HAART
H Gallais, I Ravaux, C Tomei, et al
Abstract
-
Lack of adherence to antiretrovirals caused by pill burden; efficacy and
safety of simplification
to a triple-nucleoside regimen (Trizivir)
A Biglino, M Degioanni, M Valle, et al
Abstract
-
Trizivr or Combivir plus Nevirapine as a simplified strategies in HIV-1
infected patients with viral
suppression. Results of 36 weeks of follow up of a randomized, multicenter
open-label simplification trial.
Simplifi HAART Study
A Bonjoch, J Galvez, C Miralles, et al
Abstract
-
Trizivir and Tenofovir (TT) - a simple regimen for salvage
V Latham, C Mihailidis, S Mandalia, et al
Abstract
-
Maintenance with Trizivir (TZV) or TZV + efavirenz (EFV) for 48 weeks
following a 48-week induction with TZV + EFV in ntiretroviral-naive HIV-1
infected subjects (ESS40013)
M Markowitz, C Hill-Zabala, J Lang, et al
Abstract
-
VIRUS BURDEN, IMMUNOARCHITECTURAL CHANGES IN LYMPHOID TISSUES IN HIV-1
INFECTED PATIENTS (PTS) TREATED 18 MONTHS WITH HAART WITH OR WITHOUT
PI:PROF3002 ATTILA
P Racz, C Tenner-Racz, D Praindhui, et al
Abstract
-
COMPARISON OF TRIPLE (AZT/3TC/EFV) VERSUS QUAD
(AZT/3TC/ABC/EFV) IN ARV NAIVE
PATIENTS WITH HIGH VIRAL LOAD (>100 000 C/ML) USING A DAVG ANALYSIS
AND A <5 C/ML
VL ASSAY (QUAD STUDY)
C Orkin
Abstract
-
ASSESSING ADHERENCE IN A TREATMENT SIMPLIFICATION
O Ibarra, MJ Martinez-Bengoechea, J Peral, et al
Abstract
-
AN OBSERVATIONAL COHORT COMPARISON OF ZIDOVUDINE-LAMIVUDINE-EFAVIRENZ
TO
ZIDOVUDINE-LAMIVUDINE-ABACAVIR IN ANTI-RETROVIRAL NAIVE INDIVIDUALS
N Nassar L Armas, Smillie, et al
Abstract
-
INDUCTION OF ANTIRETROVIRAL-NAIVE
HIV-INFECTED SUBJECTS WITH TRIZIVIR (TZV)
AND SUSTIVA (EFV) FOR 48 WEEKS (ESS40013)
M Markowitz, J Lang, E DeJesus, et al
Abstract
-
PROSPECTIVE STUDY OF HYPERLIPIDEMIA IN ART-NAIVE SUBJECTS TAKING
TRIZIVIR (TZV),
COMBIVIR (COM)/NELFINAVIR (NFV), OR STAVUDINE (D4T)/LAMIVUDINE
(3TC)/NFV
P Kumar, A.Rodriguez-French, M n Thompson, et al
Abstract
-
GENDER AND RACE SUBGROUP ANALYSES IN A PROSPECTIVE STUDY OF
HYPERLIPIDEMIA
IN ART-NAIVE SUBJECTS TAKING TRIZIVIR (TZV), COMBIVIR (COM)/NELFINAVIR
(NFV), OR
STAVUDINE (D4T)/LAMIVUDINE (3TC)/NFV
K. Tashima, P. Kumar, A. Rodriguez-French, et al
Abstract\
-
EFFICACY OF TRIZIVIR (TZV) AND TENOFOVIR (TDF) AS HAART FOR HIV
INFECTED PATIENTS
WITH CURRENT OR UNDERLYING REVERSE TRANSCRIPTASE (RT) RESISTANCE
P. Ruane, A. Luber, C. Gaultier,
et al
Abstract
-
GENOTYPIC RESISTANCE PROFILES IN HIV-1
REVERSE TRANSCRIPTASE DURING THERAPY
WITH TRIZIVIRâ (ZIDOVUDINE + LAMIVUDINE + ABACAVIR) IN ANTIRETROVIRAL
TREATMENT
NAIVE HIV-1 INFECTED PATIENTS
A.G. Marcelin, M. Astriti, R. Agher, et al
Abstract
|
|
|
Trizivir
Conference Citations
|
|
3rd
IAS Conference
XV
International AIDS Conference